Status:
TERMINATED
Odiparcil QT Definitive Study
Lead Sponsor:
GlaxoSmithKline
Conditions:
Fibrillation, Atrial
Atrial Fibrillation
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.
Eligibility Criteria
Inclusion
- Inclusion:
- Healthy volunteers
- Exclusion:
- Cardiac abnormalities
- Hepatic or renal insufficiency
- Anti-coagulant medications
- Bleeding history
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00437242
Start Date
October 1 2006
Last Update
June 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Austin, Texas, United States, 78744